+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Drug Overview: Epogen

  • PDF Icon

    Drug Pipelines

  • 27 Pages
  • January 2018
  • Region: Global
  • Pharma Intelligence
  • ID: 4462211
Drug Overview

Epogen (epoetin alfa; Amgen/Kyowa Hakko Kirin/Johnson & Johnson) is an erythropoiesis-stimulating agent administered by intravenous or subcutaneous injection, and is indicated for the treatment of anemia in chronic kidney disease and chemotherapy-induced anemia. The drug consists of recombinant human erythropoietin and targets the erythropoietin receptor, initiating the same pathway as native erythropoietin and triggering increased blood production in bone marrow.

Table of Contents

Product Profiles
Epogen: Anemia in chronic kidney disease
Epogen: Chemotherapy-induced anemia

List of Figures
Figure 1: Epogen for anemia in chronic kidney disease - SWOT analysis
Figure 2: Drug assessment summary of Epogen for anemia in chronic kidney disease
Figure 3: Drug assessment summary of Epogen for anemia in chronic kidney disease
Figure 4: Epogen sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country, 2015-24
Figure 5: Epogen for chemotherapy-induced anemia - SWOT analysis
Figure 6: Drug assessment summary of Epogen in chemotherapy-induced anemia
Figure 7: Drug assessment summary of Epogen in chemotherapy-induced anemia

List of Tables
Table 1: Epogen drug profile
Table 2: Epogen pivotal trial data in anemia in chronic kidney disease
Table 3: Epogen other late-phase trial data in anemia in chronic kidney disease
Table 4: Epogen sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country ($m), 2015-24
Table 5: Epogen drug profile
Table 6: Epogen pivotal trial data in chemotherapy-induced anemia
Table 7: Epogen ongoing late-phase clinical trial in chemotherapy-induced anemia